Friday, January 5, 2018

Gossamer Bio Raises $100M

San Diego-based Gossamer Bio, a new biopharma startup founded by former executives of Receptos, has raised $100M in a Series A funding, the company said late Thursday evening. Gossamer said the funding included seed funding from Omega Funds, and a Series A co-led by ARCH Venture Partners and Omega Funds. Gossamer Bio was co-founded by Faheem Hasnain and Sheila Gujrathi, M.D., former executives at Receptos. Gossamer Biosaid it is focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs of targeted patient populations. As part of the funding, Richard Lim and Otello Stampacchia of Omega Funds, Kristina Burow and Robert Nelsen of ARCH Venture Partners, and Tom Daniel, former Chairman and President of Celgene Global Research and Early Development all join the company's board of directors.